Table 1 Body, liver, relative liver weights, and length of colon.
From: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands
Group no. | Treatment | No. of mice | Body weight (g) | Liver weight (g) | Relative liver weight (g/100 g body weight) | Length of colon (cm) |
|---|---|---|---|---|---|---|
1 | AOM/DSS | 10 | 36.6 ± 5.6 a | 2.0 ± 0.5 | 5.5 ± 0.7 | 11.5 ± 2.1 |
2 | AOM/DSS/0.04% Nimesulide | 10 | 44.8 ± 5.6 b | 2.3 ± 0.3 | 5.3 ± 0.7 | 12.1 ± 1.3 |
3 | AOM/DSS/0.05% Troglitazone | 10 | 43.6 ± 6.3 c | 2.5 ± 0.5 d | 5.7 ± 1.0 | 11.4 ± 1.1 |
4 | AOM/DSS/0.05% Bezafibrate | 10 | 42.4 ± 6.4 d | 2.8 ± 0.7e | 6.6 ± 1.5 | 12.1 ± 1.4 |
5 | 0. 04% Nimesulide | 5 | 39.9 ± 7.3 | 2.0 ± 0.3 | 5.0 ± 0.9 | 12.5 ± 0.7 |
6 | 0. 05% Troglitazone | 5 | 39.8 ± 4.0 | 2.1 ± 0.3 | 5.2 ± 0.7 | 11.9 ± 0.9 |
7 | 0. 05% Bezafibrate | 5 | 46.8 ± 9.6 | 2.7 ± 0.5 | 5.8 ± 0.9 | 12.6 ± 1.4 |
8 | AOM | 5 | 42.8 ± 2.6 | 1.9 ± 0.1 | 4.5 ± 0.4 | 12.3 ± 1.2 |
9 | DSS | 6 | 34.4 ± 2.8f | 1.8 ± 0.2 | 5.2 ± 0.7 | 12.3 ± 0.6 |
10 | None | 5 | 43.2 ± 6.5 | 2.0 ± 0.2 | 4.8 ± 0.8 | 12.0 ± 0.6 |